拉丁美洲g-Csf/Peg-G-Csf市场趋势与行业增长

拉丁美洲 G-CSF/ PEG-G-CSF 市场分析和见解

发达国家和政府对癌症预防的重视程度不断提高，并采取了有意识的举措来教育早期治疗，从而促进了拉丁美洲 G-CSF 生物仿制药的销售市场。Grafeel、Colstim、Neukine 和 Filcad 是已获批准的生物仿制药，而且在发展中国家也具有成本效益且容易获得，将带来显著的市场增长。中国和印度是癌症患者数量不断增加的国家，这可能会提振拉丁美洲市场。因此，与使用原始生物制剂相比，使用生物仿制药有助于降低患者的医疗保健成本，从而增加了拉丁美洲 G-CSF 生物仿制药销售市场的需求。由于单个生物仿制药的生物制造过程复杂，生物仿制药的成本并不像仿制药那么低。自身免疫和罕见慢性疾病的日益流行预计将推动该细分市场的增长。

Data Bridge Market Research 分析称，拉丁美洲 G-CSF/PEG-G-CSF 市场预计到 2030 年将达到 4.3097 亿美元的价值，预测期内复合年增长率为 4.6%。本市场报告还深入介绍了定价分析、专利分析和技术进步。

报告指标	细节
预测期	2023 至 2030 年
基准年	2022
历史岁月	2021 (可定制至 2020-2015)
定量单位	收入（百万美元），定价（美元）
涵盖的领域	按适应症（中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长协调性缺陷等）、剂量（单药和联合用药）、给药途径（静脉注射、皮下注射）、包装（一次性使用小瓶和预填充注射器）、最终用户（医院和诊所、研究和学术机构、门诊手术中心等）、分销渠道（医院药房、网上药房、零售药房等）
覆盖国家	墨西哥、哥伦比亚、巴西、阿根廷、智利、秘鲁、厄瓜多尔、拉丁美洲其他地区
涵盖的市场参与者	USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、杭州九源基因工程有限公司、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、江苏恒瑞制药股份有限公司等。

拉丁美洲 G-CSF/ PEG-G-CSF 市场定义

粒细胞集落刺激因子 (G-CSF) 是一种用于治疗中性粒细胞减少症的药物。这是一种白细胞数量低于平均水平的疾病，是由某些形式的化疗引起的。G-CSF 的主要类型是来诺格司亭 (Granocyte)、非格司亭 (Neupogen、zarzio、nivestim、accofil)、长效 (聚乙二醇化) 非格司亭 (pegfilgrastim、neulasta、pelmeg、ziextenco) 和利培非格司亭 (lonquex)。来诺格司亭是一种糖基化重组治疗剂，其化学性质与天然存在的人类粒细胞集落刺激因子 (G-CSF) 相似或相同。各种产品包括片剂和胶囊，可治疗癌症、血液疾病、生长激素缺乏症以及慢性和自身免疫性疾病。

拉丁美洲 G-CSF/ PEG-G-CSF 市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：

驱动程序

血癌和癌症发病率不断上升

癌症是多种疾病的总称，这些疾病会影响身体的任何部位。癌症的其他术语包括恶性肿瘤和肿瘤。癌症的特征之一是异常细胞的快速形成，这些细胞生长超出正常范围，可以侵入身体的邻近部位并扩散到其他器官；后一个过程称为转移。广泛转移是癌症死亡的主要原因。

非格司亭是一种粒细胞集落刺激因子 (GCSF)，有助于增加血液中的中性粒细胞数量。非格司亭和聚乙二醇非格司亭被广泛用于在癌症化疗或放射治疗后增加白细胞。

发热性中性粒细胞减少症病例增加

发热性中性粒细胞减少症是指在严重中性粒细胞减少症期间发烧。如果患者患有中性粒细胞减少症，其感染风险可能高于平常，特定感染的严重程度也可能更高。发热性中性粒细胞减少症是癌症治疗中最常见的危及生命的并发症；其治疗通常是肿瘤急症。

发热性中性粒细胞减少症是伴有发烧的中性粒细胞减少症。中性粒细胞减少症是指血液中中性粒细胞浓度下降。中性粒细胞是一种白细胞，作为免疫系统的一部分，有助于抵抗感染。美国传染病协会将中性粒细胞减少症定义为绝对中性粒细胞计数 (ANC) 低于 1500 个细胞/立方毫米。重度中性粒细胞减少症的感染和中性粒细胞减少性发热风险急剧增加，重度中性粒细胞减少症的定义为绝对中性粒细胞计数 (ANC) 低于 500 个细胞/立方毫米。发烧定义为单次口腔温度大于或等于 101° 华氏度 (38.3° 摄氏度) 或持续体温大于或等于 100.4° 华氏度 (38.0° 摄氏度) 或更高，持续一小时或更长时间。

克制

严格的政府法规

开发非格司亭等生物仿制药的制药公司在产品审批过程中面临着重大挑战。每个国家对所有药物、治疗、疫苗和医疗器械的审批流程都不同。然而，这些审批程序很难遵循。这是因为需要各种法规和证据来证明产品的有效性和安全性。

欧洲药品管理局的监管要求确保生物仿制药与原研生物制品具有相同的高质量、安全性和有效性标准。这些要求还包括与参考产品进行严格的可比性测试，但欧盟以外的监管机构并未普遍接受这些要求。值得注意的是，如果印度批准的“类似生物制剂”、伊朗批准的“生物仿制药”、阿根廷批准的“类似生物药物”和南非批准的非原研生物制品受到欧盟批准生物仿制药所需的严格监管程序，它们可能不会获得授权。

机会

使用生物仿制药有助于降低患者的医疗成本

生物仿制药有可能从根本上改变医疗保健，为患者提供更实惠、同样有效的治疗，并为医生提供更多治疗选择。开发生物仿制药需要进行严格的分析，以证明其与参考产品的等效性，并确保其安全性、有效性和纯度没有临床意义上的差异。因此，卫生系统可以将长期节省的资金用于患者护理的整体改善。为了帮助创造一个蓬勃发展的生物仿制药市场并确保患者能够获得药物，政策制定者可以采取措施降低或消除生物仿制药的成本，并鼓励医生开出与欧洲相比更好的生物仿制药。

挑战

G-CSF 的多种副作用

粒细胞集落刺激因子 (G-CSF) 是一种用于治疗中性粒细胞减少症的药物，中性粒细胞减少症是一种疾病，某些形式的化疗会导致白细胞数量低于平均水平。G-CSF 是一种生长因子，可使骨髓产生更多的白细胞，以降低某些类型的癌症治疗后感染的风险。但是 G-CSF 有多种副作用，例如骨骼或肌肉疼痛、瘀伤、牙龈出血或流鼻血、腹泻、高烧（发烧）、呼吸困难和面色苍白、口腔、喉咙、肠道和肛门疼痛等。每 100 人中就有超过 10 人（超过 10%）会出现这些副作用。

根据 NCBI 的一项研究，大多数接受 G-CSF 的正常捐献者都会出现副作用，但程度都为轻度至中度。90% 的捐献者都经历过 G-CSF 的一些副作用。最常见的副作用是骨痛 (83%)、头痛 (39%)、身体疼痛 (23%)、疲劳 (14%) 以及恶心和呕吐 (12%)，这预计将对市场增长构成挑战。

后新冠疫情对拉丁美洲 G-CSF/ PEG-G-CSF 市场的影响

COVID-19 疫情对 G-CSF/PEG-G-CSF 市场产生了一定程度的积极影响。疫情实施了新的规范和法规，例如保持社交距离和封锁，以防止病毒传播。结果，世界各地的人们被迫待在家里，这导致了在家工作等新趋势的出现。这种居家生活导致疾病诊断和预后减少。在疫情之后，人们对自我护理、锻炼和健康的关注度增加，帮助健身应用和平台获得了显著的关注。

制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改进移植诊断市场所涉及的技术和测试结果。

最新动态

2018 年 7 月，Intas Pharmaceuticals Ltd. 的子公司 Accord Healthcare 在获得 CHMP（人用药品委员会）批准 Pelgraz®（培非格司亭）后，在欧洲推出了培非格司亭生物仿制药。该产品的推出帮助该公司拓展了其在欧洲的业务。
2022 年 3 月，Kashiv Biosciences 宣布其生物制品许可申请 (BLA) 已获美国食品药品监督管理局 (FDA) 批准，该药物为 filgrastim-ayow，这是一种参考 Neupogen 的生物仿制药。该产品以专有名称 RELEUKO 销售。

拉丁美洲 G-CSF/ PEG-G-CSF 市场范围

拉丁美洲 G-CSF/PEG-G-CSF 市场细分为适应症、剂量、给药途径、包装、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

拉丁美洲 G-CSF / PEG-G-CSF 市场，按适应症划分

中性粒细胞减少症
肿瘤学
慢性和自身免疫性疾病
血液疾病
生长激素缺乏症
其他的

根据适应症，拉丁美洲 G-CSF/PEG-G-CSF 进一步细分为中性粒细胞减少症、肿瘤学、慢性和自身免疫性疾病、血液病、生长激素缺乏症等。

拉丁美洲 G-CSF / PEG-G-CSF 市场（按剂量）

单核细胞增多症
组合

根据剂量，拉丁美洲 G-CSF/PEG-G-CSF 进一步分为单一剂量和组合剂量。

拉丁美洲 G-CSF / PEG-G-CSF 市场，按给药途径划分

静脉
皮下

根据给药途径，拉丁美洲 G-CSF/PEG-G-CSF 进一步分为静脉注射和皮下注射。

拉丁美洲 G-CSF / PEG-G-CSF 市场，按包装分类

一次性使用小瓶
预充式注射器

根据包装，拉丁美洲 G-CSF/PEG-G-CSF 进一步细分为一次性小瓶和预填充注射器。

拉丁美洲 G-CSF / PEG-G-CSF 市场，按最终用户划分

医院和诊所
研究与学术机构
门诊手术中心
其他的

根据最终用户，拉丁美洲 G-CSF/PEG-G-CSF 进一步细分为医院和诊所、研究和学术机构、门诊手术中心和其他。

拉丁美洲 G-CSF / PEG-G-CSF 市场，按分销渠道划分

医院药房
网上药店
零售药店
其他的

根据分销渠道，拉丁美洲 G-CSF/PEG-G-CSF 进一步细分为医院药房、网上药房、零售药房和其他。

拉丁美洲 G-CSF/ PEG-G-CSF 市场区域分析/见解

对拉丁美洲 G-CSF/PEG-G-CSF 市场进行分析，并根据国家、适应症、剂量、给药途径、包装、最终用户和分销渠道提供市场规模信息。

拉丁美洲 G-CSF/PEG-G-CSF 市场包括墨西哥、哥伦比亚、巴西、阿根廷、智利、秘鲁、厄瓜多尔和拉丁美洲其他地区。

墨西哥占据主导地位，因为其在最大的消费市场和较高的 GDP 中拥有主要市场参与者。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了拉丁美洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少的竞争而面临的挑战，以及销售渠道的影响。

竞争格局和拉丁美洲 G-CSF/PEG-G-CSF 市场份额分析

拉丁美洲 G-CSF/ PEG-G-CSF 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对拉丁美洲 G-CSF/ PEG-G-CSF 市场的关注有关。

在该市场开展业务的一些主要公司包括 USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、杭州九源基因工程有限公司、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、江苏恒瑞制药股份有限公司等。

SKU-69580

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET:

TABLE 2 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 3 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 5 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 7 LATIN AMERICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 LATIN AMERICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 LATIN AMERICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION)

TABLE 12 LATIN AMERICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 LATIN AMERICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 15 LATIN AMERICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 LATIN AMERICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION)

TABLE 18 LATIN AMERICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 LATIN AMERICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 LATIN AMERICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 LATIN AMERICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 LATIN AMERICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 LATIN AMERICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 LATIN AMERICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 LATIN AMERICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 31 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 32 LATAM G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION)

TABLE 33 LATAM G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 34 LATAM NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 35 LATAM ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 36 LATAM G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 37 LATAM G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 38 LATAM G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 39 LATAM G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 40 LATAM G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 41 MEXICO G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 42 MEXICO NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 43 MEXICO ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 44 MEXICO G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 45 MEXICO MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 46 MEXICO G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 47 MEXICO SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 48 MEXICO INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 49 MEXICO G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 50 MEXICO PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 51 MEXICO G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 52 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 53 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 54 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 55 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 56 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 57 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 58 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 59 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 60 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 61 MEXICO G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 62 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 63 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 64 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 65 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 66 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 67 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 68 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 69 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 70 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 71 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 72 COLUMBIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 73 COLUMBIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 74 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 75 COLUMBIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 76 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 77 COLUMBIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 78 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 79 COLUMBIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 80 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 81 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 82 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 83 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 84 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 85 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 86 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 87 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 88 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 89 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 90 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 91 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 92 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 93 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 94 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 95 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 96 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 97 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 98 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 99 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 100 BRAZIL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 101 BRAZIL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 102 BRAZIL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 103 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 104 BRAZIL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 105 BRAZIL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 106 BRAZIL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 107 BRAZIL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 108 BRAZIL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 109 BRAZIL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 110 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 111 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 112 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 113 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 114 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 115 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 116 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 117 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 118 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 119 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 120 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 121 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 122 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 123 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 124 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 125 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 126 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 127 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 128 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 129 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 130 ARGENTINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 131 ARGENTINA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 132 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 133 ARGENTINA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 134 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 135 ARGENTINA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 136 ARGENTINA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 137 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 138 ARGENTINA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 139 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 140 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 141 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 142 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 143 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 144 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 145 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 146 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 147 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 148 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 149 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 150 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 151 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 152 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 153 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 154 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 155 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 156 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 157 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 158 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 159 CHILE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 160 CHILE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 161 CHILE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 162 CHILE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 163 CHILE MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 164 CHILE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 165 CHILE SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 166 CHILE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 167 CHILE PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 168 CHILE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 169 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 170 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 171 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 172 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 173 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 174 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 175 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 176 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 177 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 178 CHILE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 179 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 180 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 181 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 182 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 183 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 184 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 185 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 186 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 187 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 188 PERU G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 189 PERU NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 190 PERU ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 191 PERU G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 192 PERU MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 193 PERU G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 194 PERU SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 195 PERU INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 196 PERU G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 197 PERU PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 198 PERU SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 199 PERU G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 200 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 201 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 202 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 203 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 204 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 205 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 206 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 207 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 208 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 209 PERU G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 210 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 211 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 212 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 213 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 214 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 215 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 216 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 217 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 218 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 219 ECUADOR G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 220 ECUADOR NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 221 ECUADOR ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 222 ECUADOR G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 223 ECUADOR MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 224 ECUADOR G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 225 ECUADOR SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 226 ECUADOR INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 227 ECUADOR G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 228 ECUADOR PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 229 ECUADOR G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 230 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 231 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 232 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 233 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 234 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 235 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 236 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 237 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 238 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 239 ECUADOR G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 240 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 241 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 242 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 243 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 244 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 245 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 246 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 247 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 248 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

图片列表

FIGURE 1 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 2 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION

FIGURE 3 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS

FIGURE 4 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: LATIN AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID

FIGURE 8 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030

FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET

FIGURE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022

FIGURE 15 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION)

FIGURE 16 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029)

FIGURE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE

FIGURE 18 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022

FIGURE 19 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION)

FIGURE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030)

FIGURE 21 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 22 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 23 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

FIGURE 24 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022

FIGURE 27 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION)

FIGURE 28 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030)

FIGURE 29 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 30 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022

FIGURE 31 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION)

FIGURE 32 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

FIGURE 36 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022)

FIGURE 39 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022)

FIGURE 40 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 41 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030)

FIGURE 43 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The Latin America G-CSF/ PEG-G-CSF Market is projected to grow at a CAGR of 4.6% during the forecast period by 2030.

What will be the market value in the future?

The future market value of the Latin America G-CSF/ PEG-G-CSF Market is expected to reach USD 430.97 million by 2030.

Who are the major players operating in the market?

The major players in the Latin America G-CSF/ PEG-G-CSF Market are USV Private Limited, Viatris Inc., Biocon, Fresenius Kabi AG, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Amgen Inc., Pfizer Inc., Sandoz International GmbH, Apotex Inc., Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., etc.

Which countries data are covered in the report?

The countries covered in the Latin America G-CSF/ PEG-G-CSF Market are Mexico, Columbia, Brazil, Argentina, Chile, Peru, Ecuador, Rest of LATAM.

Forecast Period	2024 –2030
Market Size (Base Year)	USD MILLION Request
Market Size (Forecast Year)	USD 430.97
CAGR	4.60 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

拉丁美洲 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

拉丁美洲 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

Latin America G Csf Peg G Csf Market

CAGR : 4.60 %

拉丁美洲 G-CSF/ PEG-G-CSF 市场分析和见解

拉丁美洲 G-CSF/ PEG-G-CSF 市场定义

后新冠疫情对拉丁美洲 G-CSF/ PEG-G-CSF 市场的影响

拉丁美洲 G-CSF/ PEG-G-CSF 市场范围

拉丁美洲 G-CSF/ PEG-G-CSF 市场区域分析/见解

竞争格局和拉丁美洲 G-CSF/PEG-G-CSF 市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

拉丁美洲 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

拉丁美洲 G-CSF/PEG-G-CSF 市场 – 行业趋势和 2030 年预测

Latin America G Csf Peg G Csf Market

CAGR : 4.60 %

拉丁美洲 G-CSF/ PEG-G-CSF 市场分析和见解

拉丁美洲 G-CSF/ PEG-G-CSF 市场定义

后新冠疫情对拉丁美洲 G-CSF/ PEG-G-CSF 市场的影响

拉丁美洲 G-CSF/ PEG-G-CSF 市场范围

拉丁美洲 G-CSF/ PEG-G-CSF 市场区域分析/见解

竞争格局和拉丁美洲 G-CSF/PEG-G-CSF 市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面